These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 1108258

  • 1. Immunotherapy with neuraminidase-treated cells and bacillus Calmette-Guerin.
    Kollmorgen GM, Killion JJ, Sansing WA, Cantrell JL, Bundren JC, LeFever AV.
    Surgery; 1976 Feb; 79(02):202-8. PubMed ID: 1108258
    [Abstract] [Full Text] [Related]

  • 2. Correlations between humoral immunity and successful chemotherapy-immunotherapy.
    Cantrell JL, Killion JJ, Kollmorgen GM.
    Cancer Res; 1976 Sep; 36(9 pt.1):3051-7. PubMed ID: 788896
    [Abstract] [Full Text] [Related]

  • 3. Active immunotherapy in spontaneous leukemia of AkR mice.
    Mathé G, Halle-Pannenko O, Bourut C.
    Exp Hematol; 1973 Sep; 1(2):110-4. PubMed ID: 4609352
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Acute myelocytic leukemia.
    Holland JF, Glidewell O, Ellison RR, Corey RW, Schwartz J, Wallace HJ, Hoagland HC, Wiernik P, Rai K, Bekesi JG, Cuttner J.
    Arch Intern Med; 1976 Dec; 136(12):1377-81. PubMed ID: 793552
    [No Abstract] [Full Text] [Related]

  • 6. Therapy in an intracerebral murine glioma model, using Bacillus Calmette-Guérin, neuraminidase-treated tumor cells, and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
    Albright L, Madigan JC, Gaston MR, Houchens DP.
    Cancer Res; 1975 Mar; 35(3):658-65. PubMed ID: 234790
    [Abstract] [Full Text] [Related]

  • 7. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
    Vaage J.
    Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
    [Abstract] [Full Text] [Related]

  • 8. Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guérin.
    Dubois JB, Serrou B.
    Cancer Res; 1976 May; 36(5):1731-4. PubMed ID: 773530
    [Abstract] [Full Text] [Related]

  • 9. Mechanism of Bacillus Calmette-Guérin-induced suppression of metastases in a poorly immunogenic fibrosarcoma.
    Liotta LA, Kleinerman J, Saidel GM.
    Cancer Res; 1976 Sep; 36(9 pt.1):3255-9. PubMed ID: 788897
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapeutic response of concanavalin A-bound L1210 vaccine enhanced by a streptococcal immunopotentiator, OK-432.
    Kataoka T, Oh-hashi F, Sakurai Y.
    Cancer Res; 1979 Jul; 39(7 Pt 1):2807-10. PubMed ID: 445486
    [Abstract] [Full Text] [Related]

  • 11. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
    Shapiro A, Ratliff TL, Oakley DM, Catalona WJ.
    Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
    [Abstract] [Full Text] [Related]

  • 12. Tumor regression and enhancement resulting from immunotherapy with Bacillus Calmette-Guérin and neuraminidase.
    Sparks FC, Breeding JH.
    Cancer Res; 1974 Dec; 34(12):3262-9. PubMed ID: 4471640
    [No Abstract] [Full Text] [Related]

  • 13. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU, Mavligit GM, Reed R, Burgess MA, Gottlieb J, Hersh EM.
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [Abstract] [Full Text] [Related]

  • 14. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer.
    Mathé G, Halle-Pannenko O, Bourut C, Hiu IJ.
    Johns Hopkins Med J Suppl; 1974 Feb; 3():85-102. PubMed ID: 4154074
    [No Abstract] [Full Text] [Related]

  • 15. Effect of OK-432 on immunization with mitomycin-C-treated L1210 cells.
    Ryoyama K, Murayama T, Koshimura S.
    Gan; 1979 Feb; 70(1):75-82. PubMed ID: 376388
    [Abstract] [Full Text] [Related]

  • 16. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
    Secanella-Fandos S, Noguera-Ortega E, Olivares F, Luquin M, Julián E.
    J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
    [Abstract] [Full Text] [Related]

  • 17. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
    Bockholt NA, Knudson MJ, Henning JR, Maymí JL, Weady P, Smith GJ, Eisenbraun MD, Fraser JD, O'Donnell MA, Luo Y.
    J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic factors and manipulation of immunity systemic adjuvants in cancer therapy.
    Mathé G, Florentin I, Olsson L, Bruley-Rosset M, Schulz J, Kiger N, Orbach-Arbouys S, Schwarzenberg L, Pouillart P, de Vassal F.
    Cancer Treat Rep; 1978 Nov; 62(11):1613-21. PubMed ID: 103616
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of antileukemic effect in combination of 5-fluorouracil and OK-432.
    Koshimura S, Ryoyama K.
    Cancer Treat Rep; 1977 Nov; 61(1):17-27. PubMed ID: 324619
    [Abstract] [Full Text] [Related]

  • 20. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
    Wile AG, Sparks FC, Morton DL.
    Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.